Publication date context: February 11, 2026. This regulatory news brief covers a migraine trial described as middle meningeal artery stimulation using Cadwell devices and backed by a university sponsor. The entry lists two interventions by Cadwell, the Cascade 32 PRO and the Guardian IONM System, and identifies The University of Texas Medical Branch Galveston as the sponsor. The study is registered on ClinicalTrials.gov with identifier NCT07402954 and the status is Recruiting. The record includes a direct link to the ClinicalTrials.gov page in the source materials. In this article we present the facts in a clear, regulatory oriented manner and provide a concise navigation block to locate sections quickly. Publication date context helps readers anchor this update to the current regulatory cycle and ongoing device trial activity. In this article you will find a compact navigation block and sections with precise anchors to support quick review by clinicians, regulatory teams, and device manufacturers. The information below is derived from the source entry and the linked ClinicalTrials.gov record as of the date shown in the source text.
What changed in this migraine device trial?
The record confirms a regulatory entry for a trial exploring middle meningeal artery stimulation as a potential approach to migraine management. The interventions are identified as Cadwell Cascade 32 PRO and Cadwell Guardian IONM System. The sponsor is The University of Texas Medical Branch Galveston, and the trial is indexed on ClinicalTrials.gov with identifier NCT07402954. The status is Recruiting, indicating that enrollment is ongoing or planned at the time of the listing. This update consolidates the factual elements visible in the source text and the clinical trials registry, without asserting outcomes or claims about efficacy. Readers should recognize the structure of a device trial entry, including sponsor, device designations, and a public enrollment status, as part of standard therapeutic device research reporting. This section is intended to provide context for regulatory and clinical readers who track device related studies for migraine.
Which devices are used in this trial?
The interventions listed in the source are two Cadwell devices: Cascade 32 PRO and Guardian IONM System. These entries indicate device based stimulation as part of the research protocol. The summary does not include device configuration details, endpoints, or study milestones beyond the listing. For professionals reviewing device utilization in migraine related trials, the explicit device names in the record help wire the trial to specific manufacturer offerings and support traceability in regulatory and compliance workflows. This section remains limited to identifying the devices named in the public entry and does not extend to performance characteristics or clinical outcomes.
What is the status and what should clinicians know?
Recruiting status means the study is actively seeking or enrolling participants, according to the public record. The sponsor is UTMB Galveston and the devices are Cadwell Cascade 32 PRO and Cadwell Guardian IONM System. The ClinicalTrials.gov page provides the primary public record for this trial, including the identifier NCT07402954 and a direct link to the detailed entry. Clinicians and researchers may monitor the registry page for enrollment updates, site information, and any posted milestones or amendments. The explicit listing of sponsor and devices supports accountability and traceability in regulatory communications and scientific reporting.
What are the regulatory implications for professionals?
This entry reflects standard regulatory practice for device oriented trials listed on ClinicalTrials.gov. It confirms a device based research activity conducted under a formal sponsor and with ongoing recruitment. The absence of efficacy claims in the listed text means readers should rely on the registry for official trial status and any amendments. Professionals reviewing this record should note the trial identifier and sponsor to support diligence in regulatory tracking and potential post market collaboration or oversight activities.
FAQ
- 1. What is the focus of this trial? The focus is middle meningeal artery stimulation for migraine using Cadwell Cascade 32 PRO and Guardian IONM System as listed in the source.
- 2. Who is sponsoring? The University of Texas Medical Branch, Galveston.
- 3. Where can I find more information? See the ClinicalTrials.gov record NCT07402954 with the link provided in the source.
Conclusion
Readers seeking regulatory and clinical updates should monitor the ClinicalTrials.gov entry and the sponsor communications for any enrollment changes or protocol amendments. The fact pattern here centers on two named Cadwell devices and a university sponsor, with a clear public record and a defined trial identifier. This combination supports transparent oversight for device oriented research in migraine therapy while awaiting future results. Clinicians and regulatory teams may use the provided link to access the most current trial details and status.
Disclaimer
This article is intended for professionals and is not legal advice. It reflects information available from the source text and the linked registry. For formal guidance, consult regulatory counsel or the sponsor’s official communications.
Announcement line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07402954?term=medical+device